Evidence map›Paper›PMID 35091865›Full record

ArticleMikrochimica acta2022

Photochromic immunoassay for tumor marker detection based on ZnO/AgI nanophotocatalyst.

Bing Zhang, Xue Wang, Yan Cheng

Abstract read
PubMed Publisher
In one paragraph

Article in Mikrochimica acta, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Bing ZhangShanxi Medical University, Taiyuan, 030001, China. zhangbing01@tyut.edu.cn.ORCID http://orcid.org/0000-0003-4363-919X
Xue WangTaiyuan University of Technology, Taiyuan, 030024, China.
Yan ChengShanxi Medical University, Taiyuan, 030001, China. chengyan_1976@163.com.
Shanxi Medical University · CNTaiyuan University of Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A photochromic immunoassay was built for tumor marker detection based on ZnO/AgI nanophotocatalyst. Frist, ZnO/AgI nanoparticles were synthesized and characterized by scanning electron microscopy (SEM), transmission electron microscopy (TEM), X-ray powder diffraction (XRD), and Fourier transform infrared spectrometry (FTIR). The color development is caused by tetramethyl benzidine (TMB) solution oxidated by ZnO/AgI nanomaterials. The electron transitions in ZnO/AgI nanomaterials are driven by visible light irradiation, generating photogenerated hole and oxidizing TMB to blue solution. Appropriate band width between ZnO and AgI promotes separation of photogenerated electrons and holes and enhances oxidation efficiency. A sandwich-type immunoassay was constructed based on ZnO/AgI nanomaterial as labels. The absorbance at 650 nm of reaction solution is positively correlated with antigen concentration. The developed immunoassay showed good performance for carcinoma embryonic antigen (CEA) detection in the range 0.1-7.0 ng/mL with a detection limit of 65 pg/mL. The photochromic immunoassay also exhibited preferable selectivity, repeatability, and stability. A novel colorimetric immunoassay was constructed based on ZnO/AgI photocatalyst. ZnO/AgI nanomaterials occur electron transitions under visible light irradiation and generate photogenerated hole, which can oxidize TMB to blue solution. Carcinoembryonic antigen in sample was detected sensitively due to the high catalytic efficiency of ZnO/AgI nanomaterials.

Indexed as

Photochemical ProcessesBiomarkers, TumorCatalysisHumansImmunoassayIodidesSilver CompoundsZinc OxideBiomarkers, TumorIodidesSilver Compoundssilver iodideZinc OxideAntigen detectionColorimetric detectionImmunoassayTumor markerZnO/AgI

Identifiers

PMID35091865
OpenAlexW4210352378

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.